Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Emerging Trends in Life Science Innovations: Strategies for Success

Jun 07, 2026

Introduction to Emerging Trends in Life Science Innovations

The life sciences sector is undergoing a transformative phase with a range of emerging trends reshaping the landscape. From advancements in biotechnology to personalized medicine, these innovations are set to revolutionize healthcare and improve patient outcomes. Understanding these trends and leveraging them effectively can propel companies to success.

In this blog post, we'll explore some of the key emerging trends in life science innovations and provide strategies for success in navigating these changes.

life sciences innovation

Advancements in Biotechnology

Biotechnology is at the forefront of life science innovations, offering solutions to challenges in healthcare, agriculture, and environmental sustainability. Recent advancements include CRISPR gene-editing technology, which allows precise modification of DNA, and synthetic biology, which enables the creation of new biological parts.

Companies looking to capitalize on these advancements should focus on investing in research and development, fostering collaborations with academic institutions, and staying updated with regulatory changes. Staying agile and adaptable will be crucial in this fast-evolving field.

CRISPR and Gene Editing

CRISPR technology has opened new possibilities in treating genetic disorders by allowing scientists to make precise edits to DNA. This innovation has the potential to eradicate diseases at their genetic roots, offering hope for conditions previously deemed incurable.

gene editing

Synthetic Biology

Synthetic biology combines biology and engineering, enabling the design of new biological systems. This field has applications in developing biofuels, pharmaceuticals, and sustainable agricultural practices. Companies can benefit from synthetic biology by exploring partnerships with technology firms and investing in interdisciplinary research.

Rise of Personalized Medicine

Personalized medicine is transforming the way healthcare is delivered by tailoring treatments to individual patients based on their genetic makeup. This approach enhances treatment efficacy and minimizes side effects.

To succeed in this domain, companies must prioritize data analytics and leverage artificial intelligence to interpret complex genetic data. Building strong relationships with healthcare providers and patients will also be essential to ensure the successful implementation of personalized treatments.

personalized medicine

Genomics and Data Analytics

Advancements in genomics have made it possible to sequence entire genomes quickly and affordably. Coupled with data analytics, this allows for a deeper understanding of diseases and the development of targeted therapies. Investing in robust data infrastructure and skilled personnel will be key to harnessing the power of genomics.

  • Invest in cutting-edge data analytics tools.
  • Collaborate with genomics research institutions.
  • Focus on patient-centric care models.

Integration of Artificial Intelligence

Artificial intelligence (AI) is becoming an integral part of life sciences, enhancing research efficiency and enabling the discovery of new drugs. AI algorithms can analyze vast datasets to identify patterns and predict outcomes, accelerating the innovation process.

Strategies for success include investing in AI-driven platforms, training staff in AI applications, and fostering a culture of innovation within the organization. Collaborating with AI experts and tech companies can also provide valuable insights and technological support.

artificial intelligence healthcare

Drug Discovery and Development

AI-powered drug discovery platforms can significantly reduce the time and cost required to bring new drugs to market. These platforms can identify potential drug candidates by analyzing chemical structures and biological interactions, streamlining the development process.

  1. Leverage AI to enhance drug discovery pipelines.
  2. Partner with technology companies specializing in AI.
  3. Continuously update and refine AI models.

Conclusion

The life sciences sector is poised for unprecedented growth, driven by innovations in biotechnology, personalized medicine, and artificial intelligence. By staying informed about these emerging trends and adopting strategic approaches, companies can position themselves for success in this dynamic field.

Embracing a forward-thinking mindset and fostering collaboration across disciplines will be essential to thrive in the ever-evolving landscape of life science innovations.